Real-World Adherence and Effectiveness of Inclisiran in Lowering LDL-C: Results from 1 Year of Follow-Up

Abstract Introduction Atherosclerotic cardiovascular disease (ASCVD) is a global health concern. Reducing low-density lipoprotein cholesterol (LDL-C) is critical in ASCVD prevention and treatment. Inclisiran, a novel RNA therapeutic agent, offers a promising solution by lowering LDL-C with twice-yea...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Christie M. Ballantyne, Timothy E. Graham, Lucinda J. Van Anglen, Bruce J. Iteld, Harvey Serota, Xiaoli Niu, Sean McElligott, Kelly E. Hanna, Tyler J. Varisco
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Adis, Springer Healthcare 2025-11-01
Edice:	Cardiology and Therapy
Témata:	Atherosclerotic cardiovascular disease Inclisiran LDL-C Lipid-lowering therapy Real-world adherence Statins
On-line přístup:	https://doi.org/10.1007/s40119-025-00438-0
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!